Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Panic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Panic. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-000051-34 Sponsor Protocol Number: DS/06/PDBX/01 Start Date*: 2007-09-10
    Sponsor Name:ITALFARMACO
    Full Title: Randomized, open-label, controlled and multicenter trial on a new pattern of Paroxetine up-titration for Panic Disorder. Comparison between two different dose regimens.
    Medical condition: Panic Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033666 Panic disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001060-80 Sponsor Protocol Number: AB/PD/21 Start Date*: 2007-10-11
    Sponsor Name:ABIOGEN PHARMA
    Full Title: A multicenter, parallel-group, double-blind, randomized, placebo-controlled, increasing-dose study, to evaluate preliminarily the clinical effects, the safety and tolerability of ABIO 08/01, in pat...
    Medical condition: Panic disorder
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033666 PT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021198-35 Sponsor Protocol Number: 32820 Start Date*: 2010-09-02
    Sponsor Name:University Utrecht
    Full Title: D-cycloserine (DCS) enhancement of exposure therapy in panic disorder with agoraphobia: a randomized controlled trial.
    Medical condition: panic disorder with agoraphobia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052794 Panic disorder with agoraphobia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005338-23 Sponsor Protocol Number: MKAEWC1 Start Date*: 2016-09-07
    Sponsor Name:University of Amsterdam
    Full Title: Targeting fear memory by disrupting the process of memory reconsolidation: A new intervention for panic disorder.
    Medical condition: Panic disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004860-29 Sponsor Protocol Number: Panik-Cyclo Start Date*: 2007-05-11
    Sponsor Name:Charité- Universitätsmedizin Berlin
    Full Title: D-Cycloserine supported exposure in panic disorder
    Medical condition: Panic disorder agoraphobia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003191-39 Sponsor Protocol Number: Start Date*: 2013-01-21
    Sponsor Name:University of Oxford
    Full Title: The effect of a single-dose of d-cycloserine on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized placebo-controlled trial
    Medical condition: DSM-IV Panic disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10068300 Panic attacks and disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003542-68 Sponsor Protocol Number: Start Date*: 2016-01-27
    Sponsor Name:University of Oxford
    Full Title: The effect of single-dose losartan on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized double blind placebo-controlled trial
    Medical condition: DSM panic disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10068300 Panic attacks and disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-023044-32 Sponsor Protocol Number: DCS-fMRIPanik Start Date*: 2011-08-10
    Sponsor Name:Charité Universitaetsmedizin Berlin
    Full Title: Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder
    Medical condition: panic disorder and agoraphobia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005708-17 Sponsor Protocol Number: ELB139202-05 Start Date*: 2006-03-27
    Sponsor Name:elbion AG
    Full Title: International, multicenter, randomized, double-blind, placebo controlled, two-period, cross-over study to demonstrate safety, tolerability and anxiolytic effects of 600 mg ELB139 given orally t.i.d...
    Medical condition: Male and female patients with diagnosis of concurrent panic disorder according to DSM-IV, with or without agoraphobia (DSM IV 300.21 and 300.1) according to Mini International Neuropsychiatric Inte...
    Disease: Version SOC Term Classification Code Term Level
    10037175
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001398-19 Sponsor Protocol Number: Exposition-DCS Start Date*: 2011-06-27
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: D-cycloserine augmented exposure therapy in patients with agoraphobia
    Medical condition: agarophobia with or without panic disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002649-19 Sponsor Protocol Number: 7043 Start Date*: 2010-04-07
    Sponsor Name:Tartu University Hospital Psychiatry Clinic
    Full Title: Investigation of genetic predictors of the response to SSRI treatment in patients with panic disorder
    Medical condition: panic disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022835-13 Sponsor Protocol Number: WS776945 Start Date*: 2010-10-18
    Sponsor Name:UNIVERSITA` DEGLI STUDI DI FIRENZE - DIPARTIMENTO DI PSICOLOGIA
    Full Title: The Effects of Nicotine withdrawal on Panic-like Response to Breath Holding: A Placebo-Controlled, Double-Blind, Cross-Over Patch Study
    Medical condition: healthy current smokers
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009180 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020906-14 Sponsor Protocol Number: 50591903 Start Date*: 2011-03-31
    Sponsor Name:MUMC
    Full Title: Randomized controlled trial of escitalopram versus placebo for patients with irritable bowel syndrome and panic disorder.
    Medical condition: IBS and panic disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004094-17 Sponsor Protocol Number: 40-41200-98-9269 Start Date*: 2015-11-03
    Sponsor Name:Universiteit Utrecht
    Full Title: Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias.
    Medical condition: Phobic anxiety disorders: either generalized social phobia or panic disorder with agoraphobia.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10068299 Fear symptoms and phobic disorders (incl social phobia) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-001683-29 Sponsor Protocol Number: 61393215MDD2001 Start Date*: 2019-09-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-61393215 as Adjunctive Treatment in Adults with Major Depressive Disorder with Anxio...
    Medical condition: Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious Distress with Suboptimal Response to Standard Antidepressants
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-000954-22 Sponsor Protocol Number: CI-1008-100 Start Date*: 2004-09-23
    Sponsor Name:Pfizer Global Research & Development
    Full Title: A 1-Year Open-Label Safety Extension Study of Pregabalin (CI-1008) in Patients With Anxiety Disorders
    Medical condition: Generalized Anxiety Disorder
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2006-001085-17 Sponsor Protocol Number: P1V-S01-03-06 Start Date*: 2007-08-22
    Sponsor Name:University of Bristol
    Full Title: Further development of a new model of GAD: The effect of a clinically effective and non−effective dose of lorazepam on CO2 induced anxiety
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018075 Generalised anxiety disorder LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000971-15 Sponsor Protocol Number: P1V-ANX-CT01-07 Start Date*: 2008-07-02
    Sponsor Name:University of Bristol
    Full Title: Evaluation of the effects of chronic treatment with venlafaxine (150 mg) and pregabalin (200 mg) on emotional indices of anxiety and panic induced by breathing carbon dioxide.
    Medical condition: Generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018075 Generalised anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005055-18 Sponsor Protocol Number: D1448C00012 Start Date*: 2006-05-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-centre, Double-blind, Randomised-Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Monothe...
    Medical condition: Maintenance treatment of patients with Generalised Anxiety Disorder.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022914-15 Sponsor Protocol Number: A3051123 Start Date*: 2012-03-01
    Sponsor Name:Pfizer, S.L.U.
    Full Title: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYD...
    Medical condition: Nicotine Addiction with the desire to quit smoking
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10053325 Smoking cessation therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) DK (Completed) FI (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 13:31:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA